High Growth Tech Stocks To Watch In February 2025

Over the last 7 days, the United States market has risen by 1.2%, contributing to an impressive 24% increase over the past year, with earnings forecasted to grow by 15% annually. In this favorable environment, identifying high growth tech stocks involves looking for companies that demonstrate strong innovation and adaptability in rapidly evolving sectors.

Top 10 High Growth Tech Companies In The United States

Name	Revenue Growth	Earnings Growth	Growth Rating
Super Micro Computer	29.07%	27.57%	★★★★★★
Alkami Technology	21.99%	102.65%	★★★★★★
Ardelyx	21.09%	55.29%	★★★★★★
AVITA Medical	29.48%	53.73%	★★★★★★
TG Therapeutics	29.48%	45.20%	★★★★★★
Travere Therapeutics	30.33%	61.73%	★★★★★★
Clene	61.16%	59.11%	★★★★★★
Alnylam Pharmaceuticals	21.83%	59.08%	★★★★★★
Alvotech	31.17%	100.18%	★★★★★★
Lumentum Holdings	21.25%	118.58%	★★★★★★

Click here to see the full list of 233 stocks from our US High Growth Tech and AI Stocks screener.

Let's explore several standout options from the results in the screener.

Vericel (NasdaqGM:VCEL)

Simply Wall St Growth Rating: ★★★★★☆

Overview: Vericel Corporation is a commercial-stage biopharmaceutical company focused on developing and delivering cellular therapies for sports medicine and severe burn care in North America, with a market cap of $2.83 billion.

Operations: The company generates revenue primarily from its biotechnology segment, amounting to $226.84 million. Vericel is involved in the research, development, manufacture, and distribution of cellular therapies targeting sports medicine and severe burn care markets across North America.

Vericel's recent stride in the biotech sector underscores its robust growth trajectory, with an impressive 20.4% annual revenue increase and a remarkable 42.8% surge in earnings expected annually. This performance notably outpaces the broader U.S. market's growth rates of 8.9% for revenue and 14.5% for earnings, positioning Vericel advantageously within its industry. The company’s commitment to innovation is evident from its R&D investments, crucial for sustaining long-term competitiveness in high-stakes biotech markets. Recent corporate guidance highlights this momentum, projecting a continuation of strong financial performance into 2025 with anticipated revenue growth between 20% to 23%.

• Click here to discover the nuances of Vericel with our detailed analytical health report.

• Gain insights into Vericel's past trends and performance with our Past report.

Veracyte (NasdaqGM:VCYT)

Simply Wall St Growth Rating: ★★★★☆☆

Overview: Veracyte, Inc. is a diagnostics company that operates both in the United States and internationally, with a market capitalization of approximately $3.13 billion.

Operations: Veracyte generates revenue primarily through its diagnostic products, amounting to $425.33 million.

Veracyte's recent presentation at the 2025 ASCO GU Symposium highlights its innovative strides in cancer diagnostics, showcasing the Decipher Prostate and Bladder tests which guide treatment decisions based on genomic classifiers. These tools, developed through advanced RNA analysis and machine learning, underscore a 9% annual revenue growth forecast, outpacing the broader market's 8.9%. With R&D expenses crucial to these advancements, Veracyte is set to harness its technological edge to enhance personalized medicine in oncology, aligning with an expected earnings growth of 46.23% annually. This positions Veracyte favorably as it transitions towards profitability within three years amidst a competitive biotech landscape.

• Navigate through the intricacies of Veracyte with our comprehensive health report here.

• Explore historical data to track Veracyte's performance over time in our Past section.

Dynavax Technologies (NasdaqGS:DVAX)

Simply Wall St Growth Rating: ★★★★☆☆

Overview: Dynavax Technologies Corporation is a commercial-stage biopharmaceutical company that develops and commercializes vaccines in the United States, with a market cap of approximately $1.70 billion.

Operations: Dynavax Technologies generates revenue primarily through the discovery, development, and commercialization of novel vaccines, totaling approximately $260.81 million.

Dynavax Technologies, amid a challenging biotech landscape, is navigating through significant corporate dynamics and investor activism. With an expected annual revenue growth of 16.5% and earnings growth of 33.4%, the company is outpacing the broader U.S. market but faces criticism for its acquisition strategies as voiced by Deep Track Capital. The investment firm's push for board changes underscores concerns over governance and strategic direction, particularly around maximizing returns from Heplisav. Despite these challenges, Dynavax's commitment to enhancing shareholder value is evident in its R&D spending aimed at bolstering its product pipeline, crucial for long-term sustainability in a rapidly evolving sector.

• Take a closer look at Dynavax Technologies' potential here in our health report.

• Learn about Dynavax Technologies' historical performance.

Seize The Opportunity

• Discover the full array of 233 US High Growth Tech and AI Stocks right here.
• Hold shares in these firms? Setup your portfolio in Simply Wall St to seamlessly track your investments and receive personalized updates on your portfolio's performance.
• Invest smarter with the free Simply Wall St app providing detailed insights into every stock market around the globe.

Searching for a Fresh Perspective?

• Explore high-performing small cap companies that haven't yet garnered significant analyst attention.
• Fuel your portfolio with companies showing strong growth potential, backed by optimistic outlooks both from analysts and management.
• Find companies with promising cash flow potential yet trading below their fair value.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com